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IRON DEFICIENCY ANEMIA IN HOSPITALIZED PEDIATRIC PATIENTS 
WITH ULCERATIVE COLITIS: WHAT IS THE STATUS OF PREVENTING 
IDA AND IS THERE ROOM FOR IMPROVEMENT? 
 
SARAH HUSAI MANELY 
ABSTRACT 
Background: Anemia is a common extra-intestinal manifestation of disease in patients 
with inflammatory bowel disease (IBD), and iron deficiency anemia (IDA) represents the 
most prevalent form of anemia in this population ((Gasche, Dejaco et al. 1997) (Plantz, 
Maxwell et al. 2016)). IDA can result from a combination of decreased dietary iron 
intake, impaired intestinal absorption, and excessive gastrointestinal (GI) bleeding, all of 
which can lead to decreased iron stores and poor iron utilization.  Furthermore, chronic 
IDA in children with IBD can adversely influence development and cognition, as well as 
contribute to the increased fatigue and decreased stamina observed in these patients 
(Laass, Straub et al. 2014). Treatment of IDA in pediatric patients with IBD can be with 
either oral iron supplementation or parenteral iron infusions, and both can result in an 
improvement in iron parameters and subsequent improvement in patient overall quality of 
life.  However, there is wide variability in physician practice with respect to the 
identification and treatment of IDA in pediatric patients with IBD.  
 
Objective: To assess physician practice at Boston Children’s Hospital with respect to the 
identification and treatment of IBD-related IDA in a population of patients admitted for 
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management of a flare in their underlying ulcerative colitis. This information will be 
useful to develop initiatives directed at improving recognition and management of IDA in 
this population.  
 
Methods: The Institutional Review Board (IRB) at Boston Children's Hospital (BCH) 
approved the study protocol. Patient electronic medical records were reviewed and 
abstracted from subjects with ulcerative colitis (UC) that were treated at BCH between 
January 2005 and January 2013. Each patient was assigned a study identification number 
to protect private health information, and this data was stored in a computer file behind 
the hospital’s internet firewall. Inpatient and outpatient office notes, as well as clinical 
data, were reviewed to track the identification of patients with anemia as well as 
physician management practices. All of the information collected was stored in the 
Research Electronic Database Capture (REDCap) and used for analysis. 
 
Results: A total of 243 patients met initial inclusion criteria.  Subsequent review of the 
electronic medical records revealed that only 178 patients had complete data available for 
use in our analysis. 55.5% of the 178 study subjects were anemic at admission, with a 
mean hemoglobin value of 9.32 g/dL (SD 1.89) and a mean MCV value of 77.49 fl (SD 
10.24). None of the patients in this cohort had iron studies (plasma iron, ferritin, total iron 
binding capacity) included in their admissions laboratory testing. Only 24 patients 
received oral iron supplementation during their hospital stay while none received IV iron 
infusions. Over half of the total patient cohort (78.7 %,) were not prescribed oral iron 
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supplementation at the time of discharge.  84% of patients that were discharged anemic 
remained anemic at the time of their first post-discharge ambulatory visit. Less than half 
of the total patient cohort (30.34%) had iron studies included in their follow-up 
ambulatory laboratory testing. Patients that were given iron supplementation at the time 
of discharge showed increased gains in their hemoglobin levels at follow-up compared to 
patients with no iron supplementation at the time of discharge (p <0.0001).  
Conclusion: These data suggest that there is a low prevalence with respect to the 
identification and treatment of IDA and anemia in pediatric patients with ulcerative 
colitis (UC) at admission, discharge, and follow-up clinic visits. A secondary finding was 
a statistically significant increase in hemoglobin levels in anemic patients treated with 
some form of iron supplementation. As a result, our data support both the need to 
improve recognition of IDA in pediatric patients admitted for a UC flare as well as 
document the clinical value to this effort.  Additional studies are necessary to determine 
if improved iron surveillance and therapy will improve patient quality of life, linear 
growth, and cognition in patients with IBD.  
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INTRODUCTION 
   Anemia is a global public health concern that affects about 1.62 billion people 
living in both non-industrialized and industrialized countries (WHO 2001). Iron 
deficiency is the most common form of anemia, and this typically presents as the 
microcytic anemia characteristic of iron deficiency anemia (IDA) (Camaschella 2015).  
While the prevalence of IDA appears to be on the decline, it remains the most common 
nutritional deficiency worldwide (Killip, Bennett et al. 2007).  It continues to be common 
in children and adolescents (especially female) despite mitigating public health efforts 
including  iron fortification of grain and other food stuffs (Joo, Kim et al. 2016). This is 
of particular concern in children, as iron-laden hemoglobin is central for the transport of 
oxygen to vital tissues including the brain and musculature (Lozoff, Beard et al. 2006), 
(Khedr, Hamed et al. 2008).  
 IDA can occur as a comorbidity in association with a number of different chronic 
illnesses including kidney disease, cancer, heart failure, and inflammatory bowel disease 
(Jimenez, Kulnigg-Dabsch et al. 2015). This paper will focus specifically on the 
treatment and management practices of IDA in pediatric patients with ulcerative colitis, a 
subset of IBD.  
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Figure 1: Conceptual Diagram that relates iron deficiency anemia, iron deficiency, 
and anemia in a hypothetical population. The proportion of people in the general 
population that would be affected by iron deficiency anemia is made up of an overlap 
between people with iron deficiency and people with anemia. (Figure taken from: WHO 
(2001). <WHO_NHD_01.3.pdf>. Geneva, Switzerland, World Health Organization) 
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Ulcerative Colitis 
 Ulcerative colitis is an autoimmune disease characterized by inflammation 
occurring in the mucosa lining the colon and rectum. Inflammation in UC only affects the 
mucosa and submucosa of the large intestine. Based on the location of the disease, UC 
can be categorized into three different subgroups: proctitis, left sided colitis, and 
pancolitis. Proctitis is characterized by inflammation limited to the mucosa of the rectum, 
left sided colitis is characterized by inflammation extending beyond the rectum to the 
level of the splenic flexure, and pancolitis is characterized by diffuse inflammation 
throughout the mucosa of the entire rectum and colon. In some patients, the extent of the 
disease can change over time, especially early in the course of disease (da Silva, Lyra et 
al. 2014).  
The incidence of UC in adult and pediatric populations is on the rise, and this 
appear to be even more evident in developing parts of the world (Goh and Xiao 2009).  
When acutely ill, patients present with symptoms of abdominal pain, bloody diarrhea, 
and rectal bleeding. Due to the chronic nature of this disease, patients typically 
experience a waxing and waning clinical course with periods of higher disease activity 
(flare) occurring between periods of disease quiescence (remission). The severity and 
length of time a child experiences active disease can impact negatively on growth and 
development (Rufo, Denson et al. 2012). Disease activity and inflammation can also 
impact adversely on the absorption of micronutrients leading to micronutrient 
deficiencies, including iron deficiency (Rufo, Denson et al. 2012).   One study found that 
21% of patients with UC were anemic, and that the frequency of anemia in patients with 
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IBD (both CD and UC) is higher in the inpatient setting compared to the outpatient 
setting (Rogler and Vavricka 2014). 
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Figure 2. Different subgroups of Ulcerative Colitis. (Left) Proctitis is restricted to 
inflammation in the rectum. (Center) Left-sided colitis is when inflammation extends 
from the rectum towards the splenic flexure. (Right) Pancolitis is when the inflammation 
extends throughout the rectum to the whole colon. (Figure taken from: 
halstedsurgery.org) 
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Iron homeostasis  
 Systemic iron homeostasis is regulated by hepcidin, a peptide made in the liver. 
During periods of inflammation, inflammatory cytokines (such as IL-6) released from 
damaged tissue will travel to the liver and trigger the expression of hepcidin. Hepcidin is 
a type II acute phase reactant protein (Kossiva, Soldatou et al. 2013).  Increased hepcidin 
levels reduce iron levels in circulation by inhibiting that activity of ferroportin a cellular 
iron efflux transporter located in membranes of the basolateral surface of duodenal cells, 
as well as circulating macrophages. When levels of hepcidin are high in circulation, the 
expression of ferroportin is decreased and as a result, iron is retained within duodenal 
enterocytes and macrophages (Camaschella 2017).  As a result, in the presence of 
hepcidin, iron is not available for erythropoiesis.  Since the life cycle of an intestinal 
epithelial cell is about 4-5 days, the hepcidin-trapped iron in the enterocytes is typically 
lost in the stool and never makes it into circulation (Rogler and Vavricka 2014).  
 Circulating hepcidin levels are regulated at the level of the liver in response to  
the perceived amount of iron in the body. IDA typically results in a suppression of serum 
hepcidin levels and increased iron absorption from the lumen of the intestine.  However, 
this important iron regulatory protein can also serve as an acute phase reactant and result 
in a sequestration of iron stores in the context of inflammation or infection (characterized 
as anemia of chronic disease). As such, the inflammation observed in patients with active 
IBD can result in high circulating levels of hepcidin. Nevertheless, overall expression of 
hepcidin is most closely link to iron stores (Rogler and Vavricka 2014).  
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Figure 3. Hepcidin regulation of iron homeostasis. Hepcidin is a peptide hormone 
made in the liver. It works by inhibiting the ferroportin transporter in duodenal cells and 
in macrophages, in response to iron overload and inflammatory cytokines. (Figure taken  
from: openi.nlm.nih.gov) 
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Different types of IDA  
The causes of IDA in pediatric patients with IBD are multifactorial, encompassing 
features from both anemia of chronic disease (ACD) and iron deficiency anemia (Rogler 
and Vavricka 2014). Consequently, treatment approaches to correct iron deficiency 
anemia differ according to whether there is a functional deficiency of iron stores, an 
absolute depletion of iron stores, or a combination of the two (Akkermans, Vreugdenhil 
et al. 2016).  
IDA can develop in patients that have a chronic infectious disease or 
inflammation, mediated by the release of inflammatory cytokines including interleukin 6 
(IL-6), and this can lead to the development of the functional iron deficiency 
characterized by ACD (Dignass, Gasche et al. 2015). Functional iron deficiency occurs 
when there is not a fluid supply of iron available for incorporation into erythroid 
precursors, even when there is an adequate supply of iron stores in the body (Thomas, 
Hinchliffe et al. 2013).  Functional iron deficiency is not typically responsive to oral iron 
supplementation.  
In most clinical scenarios, IDA is occurs as a result of excessive blood loss. More 
specifically, IDA in patients with IBD typically results from chronic gastrointestinal 
blood loss. Inflammation in the intestine also increases the likelihood of poor iron 
absorption from food ingested. This type of absolute iron deficiency can be corrected 
with iron supplementation (Jimenez, Kulnigg-Dabsch et al. 2015). However, in the 
presence of inflammation, physicians may be less apt to treat IDA because of the belief 
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that enteral iron supplementation may aggravate the inflammation (Laass, Straub et al. 
2014). 
Identifying IDA 
Different laboratory parameters have been defined in an effort to standardize the 
classification of iron-deficiency anemia in pediatric patients with IBD. The normal ranges 
for these parameters have been adjusted for gender and age.  A common hematologic 
work-up for anemia includes measurements of hemoglobin, albumin, and mean 
corpuscular volume (MCV); iron studies including ferritin levels (iron stores), transferrin 
iron binding capacity (TIBC), and serum iron. Low values for hemoglobin and MCV are 
used to diagnose anemia (Rufo, Denson et al. 2012). 
 In addition, patients with IBD may also have serum inflammatory markers such 
as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) included in their 
laboratory testing to provide information about the status of inflammation. These are non-
specific markers that can only suggest that there is any type of inflammation in the body 
rather than signify the specific site of disease (Cioffi, Rosa et al. 2015). CRP is a protein 
produced by hepatocytes in response to increased IL-6 cytokine in circulation. The levels 
of CRP in circulation range from 5 to 200 mg/L, with higher values indicating that the 
inflammatory process is active. The ESR measures the distance that red blood cells have 
traveled after one hour in a vertical tube of non-coagulated blood; longer distances 
traveled in one hour indicate greater inflammation in the body.  
 Interpreting all of these parameters together can sometimes be daunting. For 
example, serum ferritin levels may be or high or normal - even in the presence of iron 
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deficiency or empty iron stores (Dignass, Gasche et al. 2015).  This relates to the role that 
ferritin plays as an acute phase reactant, so its serum concentrations changes in response 
to levels of active inflammation in the body.  
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Figure 4. Evaluation for low hemoglobin levels in pediatric patients.  Levels of 
hemoglobin and MCV are used to determine final status of anemia in pediatric patients. 
(Figure taken from: Janus, J. and S. K. Moerschel (2010). "Evaluation of anemia in 
children." Am Fam Physician 81(12): 1462-1471. 
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Low treatment of IDA in pediatric patients with IBD 
There are currently guidelines available for practicing gastroenterologists that 
articulate strategies to evaluate and treat IDA in patients with IBD (Gasche, Berstad et al. 
2007). Despite this, anemia remains an under addressed comorbidity, especially in 
pediatric patients with IBD (Janus and Moerschel 2010). It is posited that the reason that 
IDA is less commonly treated in this patient population is because physicians assume that 
addressing the underlying inflammation is likely the best way to correct IDA.  As such,  
IDA receives less attention than other prominent symptoms of IBD including diarrhea 
and abdominal pain (Rogler and Vavricka 2014).  This paradigm is even more typical in 
the treatment of patients with IBD in the inpatient setting (Goodhand, Kamperidis et al. 
2012).   
Treating patients with IDA with iron supplementation has been shown to improve 
quality of life and cognitive function in patients with chronic kidney disease (Wells, 
Lewis et al. 2006).  However, more research is needed in pediatric patients with IBD to: 
show which types of iron replacement therapy is most effective and under what clinical 
circumstances, assess the relationship between iron supplementation and exacerbations of 
colonic inflammation, and discern in repletion of iron stores improves overall quality of 
life.  
Treatment options for IDA in IBD patients 
Iron supplementation has been proven to increase hemoglobin levels and reduce 
the prevalence of anemia (Goodhand, Kamperidis et al. 2012). According to the 
European Crohn’s and Colitis Organization (ECCO), the primary objective of iron 
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supplementation is to improve hemoglobin levels and iron stores (Dignass, Gasche et al. 
2015).  
Oral iron supplementation is often the first line of therapy considered to treat IDA 
(Killip, Bennett et al. 2007). However the limitations of oral iron supplementation 
include poor absorption from the gut during periods of inflammation, lack of compliance 
in children, and a slow onset of action. 
Another form of therapy is intravenous (IV) iron supplementation. IV iron 
supplementation has been shown to be effective in treating adults with IBD, and existing 
formulations can replete iron stores over the course of as few as one or two infusions 
(Lee, Kolber et al. 2012). Furthermore, the issue of compliance is circumvented. 
However, there is a lack of pediatric studies demonstrating the safety and efficacy of IV 
iron supplementation to correct for IDA (Danko and Weidkamp 2016). Consequently, the 
lack of evidence to guide clinicians in the use of IV iron supplementation has historically 
hindered the treatment of IDA in children with IBD.  
The importance of treating IDA in the pediatric population 
IDA in pediatric patients has been called a “pediatric tragedy” because it is a 
preventable condition but has not been sufficiently treated (Buchanan 1999). Throughout 
infancy and early childhood, sufficient iron and hemoglobin levels are important to 
ensure the progression of normal neurocognitive development (Khedr, Hamed et al. 
2008). There have been many studies in infants (0-24 months of age), pre-school 
children, and school age children (>24 months of age) demonstrating an association 
between low scores on mental and cognitive developmental tests to iron deficiency 
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(Lozoff, Jimenez et al. 2000). Furthermore, the World Health Organization (WHO) 
issued a report drawn from studies performed in eight different countries and 
demonstrating that IDA is consistently related to delays in the psychomotor and cognitive 
development in infants. In adolescents, especially females that are menstruating and 
regularly losing blood, low iron and hemoglobin leads to increased fatigue and poor 
concentration (Wells, Lewis et al. 2006).  
In patients with IBD, IDA can recur quickly after a patient has completed oral or 
IV iron supplementation, especially if patient experiences recurring, continuing, or 
worsening GI blood loss. Therefore it is important to routinely monitor for the presence 
of anemia in pediatric patients with IBD. Addressing anemia in this population has been 
shown to result in an overall improvement in their quality of life (Blumenstein, Dignass 
et al. 2014).  
The current literature suggests there are insufficiencies in the monitoring of iron 
status and implementation of therapy. We sought to define treatment practices employed 
by gastroenterology specialists at BCH related to IDA therapy in pediatric patients with 
increased UC disease activity. We hypothesized that there would be an inadequate 
identification and active treatment of IDA symptoms in this patient population.   
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METHODS  
Study design  
We conducted a retrospective cohort study to determine the frequency of anemia 
testing and treatment in pediatric patients with ulcerative colitis admitted to a tertiary care 
hospital for management of a disease flare. Patients admitted from January 2005 through 
January 2013 were included in this study. Patients were assigned a study ID to protect 
private health information and to maintain anonymity. Demographic data included date of 
birth, gender, date of IBD diagnosis, and UC phenotype. A list of medications at the time 
of admission enabled us to capture if iron supplementation had already been incorporated 
in the treatment regimen. 
In addition, information during hospitalization included laboratory data and 
treatment interventions with respect to iron supplementation, blood transfusions, 
parenteral nutrition, and IBD related medications.   
Study Population 
243 Patients (≤ 21 years of age) with the diagnosis of ulcerative colitis and 
admitted to the Gastroenterology inpatient service at Boston Children’s Hospital, were 
included in this study.  None of the patients had a history of renal disease, hematologic 
disease, or oncologic disease.  After review of these preliminary inclusion and exclusion 
criteria, only 178 patient charts had complete hematological data at admission, discharge, 
and follow up clinic visits and were used in final data analysis. Patients were 
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characterized for their UC phenotype into three different subgroups: pancolitis, left-sided, 
and proctitis.  
Data Collection 
Data was extracted from the Boston Children’s Hospital medical record database, 
PowerChart (by Cerner®). Specific patient data from the electronic medical record was 
entered on a Case Report Form (CRF) stored in an electronic database called Research 
Electronic Data Capture (REDCap). This allowed for easy data collection and accuracy in 
reporting. The CRF for this study contained 10 sections: demographics, exclusion 
diagnoses, admissions clinical data, medications on admissions, discharge clinical data, 
hospital intervention, follow up clinical data, admission lab, discharge lab, follow up 
labs.   
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Figure 5. Demographic Information – CRF. CRF showing demographic information 
collected for the study.  
 18 
Figure 6. Clinical Data from Admissions. This CRF documents clinical data of the 
patient on the day they were admitted to the hospital service.  
 19 
Figure 7. Information about medications on admission. This CRF documents what 
type of medication the patient was on at the time of admission.  
 20 
Figure 8. Hospital Interventions. CRF showing if any form of iron supplementation 
was provided. It also documents what medications the patient was on. 
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Figure 9. Laboratory tests from a follow-up clinic visit. CRF showing a typical 
laboratory test including a complete blood count, liver panel, and iron study.  
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Assessment of anemia  
Laboratory data was extracted from the time of admission, at discharge, and at the 
follow up clinic visits. Laboratory testing included CBC with differential, CRP, ESR, 
liver panel (includes albumin), and iron studies. The iron status was evaluated according 
to age and gender using standards from the second National Health and Nutrition 
Examination Survey using cutoffs set at the bottom 2.5% for hemoglobin and for MCV.  
The cut-off values for hemoglobin in the diagnosis of anemia are <11 g/dL in children 
ages 6 months – 6 years old; <12g/dL in children between the ages of 6 and 14; <13g/dL 
in adult males; and <12 g/dL in adult non-pregnant females; <11g/dL in adult pregnant 
females (Yip, Johnson et al. 1984). The cut-off value for MCV in the diagnosis of 
microcytic anemia are <81 fl for adult males and <87 fl in adult females (Yip, Johnson et 
al. 1984). 
Statistical Analysis 
Data from the CRF instruments in REDCap were exported to statistical analysis 
software (SAS 9.4). We used descriptive statistics to summarize characteristics of 
patients who were either anemic or non-anemic at the time of admission. Physician 
behavior was assessed by extrapolating information from whether or not iron testing was 
incorporated in the laboratory testing, whether or not the patient was given iron 
supplementation during their hospitalization, and whether or not the patient was 
discharged with iron supplementation. Continuous variables were calculated with mean, 
standard deviation, and median with interquartile ranges; categorical variable are reported 
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as percentages. Missing data was not excluded but rather reported as imputation values 
using median values.  
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RESULTS 
 
Patient Population 
 A total of 178 patients admitted with a UC flare and hospitalized at Boston 
Children’s Hospital had complete hematological laboratory data at admission, discharge, 
and one follow-up visit in the Gastroenterology ambulatory clinic. Over half of the study 
cohort consisted of females (59%). More than half of the total cohort had a UC phenotype 
of pancolitis (66%).   None of the patients in this study had iron studies included with 
their admission laboratory testing.   
 
Table 1. Demographic information of the study group. 
Characteristics of the study cohort identified by electronic 
medical records. 
N (total): 178 
Male/Female: 73/105 
 
Median age (IQR): 
 
13.8 (IQR 4.2) 
 
UC Phenotype: 
 
Pancolitis  
117 
Left sided 56 
Proctitis 5 
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Admission Data 
55. 5% of the patients were anemic at the time of admission (N=178). The mean 
hemoglobin value for this anemic patient cohort was 9.32g/dL (SD 1.89); the mean MCV 
value for this same cohort was 77.49 fl (SD 10.24). 20 patients out of the total 178 cohort 
were taking oral iron at the time of admission.  
Information about inflammatory markers at admission 
Only 152 out of the 178 patients had a CRP drawn with their laboratory testing 
during admission; this cohort includes both anemic and non-anemic patients. The median 
CRP value was 1.11 (IQR 3.02) for the entire patient cohort (N=152).  
82 patients with a CRP value at the time of admission were also anemic. The 
median CRP value of this cohort was 1.49 (IQR 3.6).   
Hospital interventions and outcomes 
 During a patient’s hospital visit – from day of admission to day of discharge – we 
followed any changes in medication or therapy that patients received. This included the 
provision of packed red blood cell transfusions (PRBC), IV iron infusion, or oral iron 
supplementation; as well as any changes made in their IBD medications. The average 
length of stay during the hospital for the entire cohort (N =178) was 7 days (IQR of 9).  
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Oral Iron Supplementation 
24 patients received oral iron supplementation during their hospitalization. The 
rest of the 158 patients from the study cohort (N=178) had no oral iron supplementation 
at the time of admission nor did they receive oral iron supplements during their 
hospitalization. 
Intravenous Iron Supplementation 
 No patient received an intravenous iron infusion during hospitalization (N=178).  
23 patients received parenteral nutrition with added iron.  
PRBC Transfusions 
Less than half of the patients hospitalized (21.9%) received one unit of PRBC 
transfusions by the treating team. The hemoglobin level at admission of these patients 
had a mean value of 8.45 (SD 2.3) compared to the admission hemoglobin mean value of 
Table 2. Treatments during hospitalization. Number of patients treated 
during admission classified by anemia status at admission.  
 
 Non- anemic (N= 80) Anemic (N = 98) Total (N=178) 
PRBC 
Transfusion 6 33 39 
 
IV Iron infusion 0 0 0 
 
Oral iron 
supplementation  
3 21 24 
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10.1 g/dL (SD 1.5) (p <0.0001) for those pediatric patients with UC that did not receive 
PRBC transfusions.  
Discharge Hematological Data and Prescribed Treatments 
Patients treated with oral iron during their hospitalization (N=24) had a mean 
discharge hemoglobin value of 9.34 (SD 1.3). The patients that had received a PRBC 
transfusion (N=39) had a mean discharge hemoglobin value of 10.16 (SD 1.3).  The mean 
discharge hemoglobin value for all 178 patients was 10.91 (SD 1.76). 100 patients were 
discharged from the hospital anemic with a mean hemoglobin value of 9.78 (SD 1.2). 
Less than a quarter of the total study cohort (21.3%, N=178) was prescribed oral iron 
supplements at the time of their discharge.  
 
Table 3. Laboratory parameters at time of discharge.  Status of anemia at 
discharge.  
 Non- anemic  
(N=78) 
Anemic 
 (N =100) 
Total 
 (N=178) 
Mean hemoglobin g/dL 
(SD) 
12.36  
(SD 1.16) 
9.78  
(SD 1.2) 
10.91 
 (SD 1.76) 
Mean MCV fl (SD) 84.5  
(SD 6.2) 
80.1  
(SD 8.8) 
82.04 
 (SD 8.1) 
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Gender Differences in Treatments for Anemia  
Females were 56% more likely to be treated with PRBC or oral iron 
supplementation than their male counterparts, with a relative risk ratio of 1.56 (CI 0.85-
2.9).  Controlling for hemoglobin, the odds of females receiving treatment for anemia 
(PRBC or oral iron supplementation) was 1.2 fold relative to the the odds of a male (CI 
1.61-2.62). In this analysis, the overall odds of anemia treatment were 0.58 fold the odds 
of no treatment for each one gram/dL increase in hemoglobin. In addition, female 
patients were less likely to be discharged on oral supplementation than their male 
counterparts with a relative risk ratio of 0.95(CI 0.54-1.69).  
Follow up  
The length between the date of discharge and the date of the next follow up clinic 
visit had a median value of 28 days (IQR 26).  The mean hemoglobin value for the entire 
cohort (N=178) at follow up lab testing was 11.42 (SD 1.78) and had a mean MCV value 
of 81.8 (SD 13.28). 83 patients from the study cohort (N=178) were anemic at follow-up. 
20.5% of the patients from this cohort (N=83) were prescribed oral iron supplementation 
at discharge. 84% of patients at follow-up (N=83) were discharged anemic and remained 
anemic up to the follow up clinic visit.  Figure 10 shows that anemic patients treated with 
oral iron supplementation at the time of discharge had a steeper increase in hemoglobin at 
the time of follow-up, compared to those that did not receive oral iron supplementation at 
discharge. 
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Figure 10. Average hemoglobin levels over time. Anemic patients discharged on oral 
iron supplementation demonstrated greater marginal gain in hemoglobin from discharge 
to follow-up than those not supplemented.  
 
Iron studies at follow-up 
54 of the 178 patients got plasma iron testing at the follow up appointment; 32 
underwent ferritin testing; 32 underwent TIBC testing. The median plasma iron level for 
the cohort (N=54) was 31 (IQR 45). For the patients that had a TIBC included in their 
hematological laboratory data (N=32), the mean TIBC value was 414.53 (SD 92.7). For 
the patients that had a ferritin level taken at the time of their follow up laboratory testing, 
the median value for ferritin was 12.4 (IQR 18.2). 
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DISCUSSION 
Pediatric patients with IBD are at increased risk for becoming iron deficient and 
anemic with worsening progression to iron deficiency anemia. This study provides 
information on the current status of management of iron deficiency anemia in pediatric 
patients admitted for increased ulcerative colitis disease activity at Boston Children’s 
Hospital. There are two significant findings from this study that are of clinical 
importance. First, there is insufficient identification of iron status at the times of 
admission, discharge, and follow-up clinic visits, which suggests that the clinical profiles 
of patients’ may not always be comprehensive. Second, the high prevalence of anemia at 
discharge (56%) (Table 3) and at follow-up clinic visits (84%) suggests there is 
insufficient treatment of anemia in pediatric patients with increased UC disease activity.  
 Among the 178 patients in the study, none had iron studies incorporated in their 
admissions laboratory tests. We do not have sufficient data regarding baseline iron 
parameters in our study cohort so we are unable to comment on the status of IDA 
management and treatment in this particular patient population. This first finding 
supports our hypothesis that there is inadequate testing for iron deficiency anemia in 
pediatric patients with increased ulcerative colitis activity. Without complete information 
about iron stores, physicians delay the therapeutic benefits of early detection and 
treatment of anemia in their patients with IBD. It is important to treat anemia in pediatric 
patients with IBD as soon as it is detected to relieve fatigue and poor concentration, 
improve a patient’s quality of life, and to reduce the need for subsequent blood 
transfusions (Jimenez, Kulnigg-Dabsch et al. 2015). Even treating for iron deficiency in 
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the absence of anemia can minimize fatigue. In fact, studies on patients with chronic 
renal failure that are anemic have shown improvements in quality of life and cognitive 
function in response to treatment with intravenous iron (Wells, Lewis et al. 2006).  The 
same iron replacement therapy could be used to treat pediatric patients with IBD and 
similar outcomes could be expected in these patients. 
Current guidelines to diagnose anemia include hemoglobin and MCV values 
(Thomas, Hinchliffe et al. 2013). Appropriate laboratory parameters that should be 
included with these parameters to test for the status of iron stores in the body include 
ferritin, transferrin, and TIBC (Gasche, Berstad et al. 2007).Since adequate iron stores are 
necessary for proper hemoglobin production, the determination of the availability of iron 
is important to help the physician understand the underlying causes for anemia in their 
patients and also to determine appropriate course of treatment ((Akkermans, Vreugdenhil 
et al. 2016), (Thomas, Hinchliffe et al. 2013)). While low hemoglobin and MCV values 
are useful in diagnosing anemia, they are better parameters for assessing changes over a 
longer period of time in weeks or months; iron studies that include ferritin are helpful for 
assessing more acute changes in iron availability (Thomas, Hinchliffe et al. 2013). 
Furthermore, hemoglobin levels vary with age and gender, so inclusion of additional 
laboratory parameters offers physicians a more comprehensive view of their patients’ 
clinical presentations. 
 Patients with IBD, and especially those admitted for a UC flare, also require a 
CRP drawn with their laboratory tests. Although CRP is a non-specific disease marker of 
inflammation, especially for characterizing inflammation in patients with UC, it has a 
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short half-life when compared to other acute phase proteins (Henriksen, Jahnsen et al. 
2008).  A higher CRP value is indicative of ongoing and active inflammation, while a 
lower value is indicative of inflammatory resolution. The GI treating team can interpret 
changes in the CRP values to reflect primarily IBD-related disease activity if the patient 
has no other acute or chronic inflammatory processes (Cioffi, Rosa et al. 2015).  A more 
specific metric for an IBD disease activity can be derived from validated indices 
including the pediatric ulcerative colitis activity index (PUCAI) (Rufo, Denson et al. 
2012).  In our study however, coincident PUCAI scores were not available with a 
patient’s laboratory data, so we are unable to comment on how changes of disease 
activity could have affected anemia or iron parameters.  
In Table 1, we illustrate the frequencies of three different UC phenotypes. Despite 
the differences in disease location, our study found no significant correlation between 
severity of anemia and UC geographic phenotype. This contrasts to previous studies, 
which demonstrated that children with extensive colitis were strongly associated with 
more severe anemia (Gerasimidis, Barclay et al. 2013). The lack of association in our 
study may be due to our small sample size or it could suggest that there are multiple 
causes of anemia in pediatric patients with IBD besides basic iron malabsorption. 
Additional causes are associated with GI bleeds, bloody diarrhea, and a poor diet in iron.  
 We hypothesized that the 34 patients that received PRBC transfusions during their 
admission (see table 2) had worse conditions of disease activity and symptomatology at 
the time of admission. This is commonly seen by treating teams when caring for children 
with IBD that are hemodynamically unstable and require PRBC transfusions (Bayraktar 
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and Bayraktar 2010). A small percentage of patients received oral iron supplementation 
during their hospital admission (see table 2). One possible explanation for the inadequate 
use of oral iron supplementation is that physicians are reluctant to treat anemia with oral 
iron because it can exacerbate inflammation and cause further symptoms of nausea and 
diarrhea (Goodhand, Kamperidis et al. 2012). In addition, non-absorbed iron can result in 
oxidative stress in the intestinal lumen, and in animal studies, free iron was shown to 
increase colon carcinogenesis (Liao, Seril et al. 2008). For children with active disease, a 
physician’s first priority is to achieve remission; once this has been achieved they may be 
more reluctant to induce more risk or discomfort by introducing oral iron 
supplementation (Goodhand, Kamperidis et al. 2012). Nevertheless, in our study oral iron 
supplementation was used rather than IV iron. None of the patients in the study received 
parenteral iron supplementation. The literature suggests that oral iron is typically utilized 
more frequently in comparison to IV iron supplementation because it is inexpensive and 
the current lack of research examining parenteral iron supplementation in pediatric 
patients with IBD make physicians reluctant to use this option (Danko and Weidkamp 
2016). Recently however, different research groups have started testing the use of IV iron 
sucrose to treat IDA in pediatric patients with IBD. These studies show that periodic 
parenteral iron supplementation that is coordinated with regular biologic infusions, are 
safe and effective for the management of IDA in children with IBD (Danko and 
Weidkamp 2016) (Plantz, Maxwell et al. 2016). Based on the recent developments in iron 
replacement therapy in pediatric patients with IBD, our data in this study further 
underscored the inadequate utilization of iron supplementation at BCH. 
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In many cases, physicians will treat a UC flare with different types of medications 
such as steroids, immunosuppressants, and biologics that target inflammatory proteins. 
Steroids are used as a short-term change in IBD therapy in response to acute flares 
because they act quickly to bring the disease under control.  Our study did not evaluate 
the frequencies of the changes in IBD medications during hospitalization.  However,  we 
assumed that patients admitted for a flare would get treated with some type of steroid or 
immunosuppressant based on common practice by IBD treating teams (Rufo, Denson et 
al. 2012). Interestingly, our results showed that hemoglobin values do not always 
improve in response to treatment of the underlying UC (figure 4). Current guidelines for 
the management of IBD in patients with IDA advocate the treatment of anemia in 
addition to the management of disease symptoms (Gasche, Berstad et al. 2007). One 
study suggests that by limiting the scope of treatment to a patient’s UC flare, symptoms 
of iron deficiency and anemia are likely to worsen  (Wells, Lewis et al. 2006).  
The persistence of anemia in patients with IBD is a significant issue. Numerous 
studies have shown that regardless of disease activity, anemia and iron deficiency anemia 
persist in pediatric patients with IBD (Powers, Daniel et al. 2016) (Wells, Lewis et al. 
2006). In our study, there was a large portion of patients that were discharged anemic and 
remained anemic at follow-up (84%). This finding supports our hypothesis that anemia is 
under-treated in this patient population even after disease activity is brought under 
control. Furthermore, we showed that there is a low occurrence for iron testing at follow-
up clinic visits. The results from this study provided the impetus for this research group 
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to study the treatment of anemia in conjunction with management of IBD in pediatric 
patients at BCH. 
 This study’s analysis was limited since it was a retrospective investigation 
and the available data were not designed for our hypotheses. Furthermore, there was 
missing information on different parameters that could have been used in our analyses. 
With the prospective study on the active management of iron deficiency in pediatric 
patients with IBD, we may be able show with greater certainty the effectiveness of 
treatment to sustain iron stores and help with patient’s quality of life. 
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